Juno Therapeutics Reports First Quarter 2015 Financial Results
May 11, 2015 16:05 ET
|
Juno Therapeutics
Conference call to be held on Monday, May 11, 2015 at 5:00 p.m. Eastern Time
- Positive momentum on clinical trials and research continues
- Multiple strategic transactions...
Juno Therapeutics Strengthens Multiple Capabilities Through Acquisition of Stage Cell Therapeutics
May 11, 2015 16:02 ET
|
Juno Therapeutics
Transaction Provides Transformative Cell Selection and Activation Capabilities, Advanced Manufacturing Automation, Improved Supply Chain, and Lower Expected Cost of Goods
Initial Payment of...
Juno Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
May 06, 2015 07:30 ET
|
Juno Therapeutics
SEATTLE, May 6, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2015 Health Care Conference at...
Juno Therapeutics to Report First Quarter 2015 Financial Results on Monday, May 11
May 05, 2015 08:00 ET
|
Juno Therapeutics
SEATTLE, May 5, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) will announce financial results for the first quarter of 2015 on Monday, May 11, 2015 after the close of U.S.-based...
MedImmune and Juno Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
GAITHERSBURG, Md. and SEATTLE, April 23, 2015 (GLOBE NEWSWIRE) -- MedImmune, the global biologics research and development arm of AstraZeneca, and Juno Therapeutics, Inc., a biopharmaceutical company...
Juno Therapeutics' CAR T Cell Product Candidate JCAR017 Continues to Demonstrate Encouraging Outcomes in Pediatric Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia
April 21, 2015 10:30 ET
|
Juno Therapeutics
SEATTLE, April 21, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...
Juno Therapeutics Announces Patent Litigation Settlement
April 06, 2015 08:00 ET
|
Juno Therapeutics
SEATTLE, April 6, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it entered into a settlement agreement to resolve litigation with the Trustees of the University...
Juno Therapeutics Reports Fourth Quarter and 2014 Financial Results
March 18, 2015 16:02 ET
|
Juno Therapeutics
Conference call to be held on Wednesday, March 18, 2015 at 5:00 p.m. Eastern Time
Positive momentum and progress on clinical trials continues
Strong year-end cash position of $474.1...
Juno Therapeutics to Report Full Year and Fourth Quarter 2014 Financial Results on Wednesday, March 18
March 11, 2015 08:00 ET
|
Juno Therapeutics
SEATTLE, March 11, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2014 on Wednesday, March 18, 2015...
Juno Therapeutics to Present at March 2015 Investor Conferences
February 24, 2015 08:00 ET
|
Juno Therapeutics
SEATTLE, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it will webcast its presentations at the below listed investor conferences in March.
Hans...